Caribou Biosciences, Inc.
CRBU • NASDAQ
Caribou Biosciences, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Rachel E. Haurwitz, with a market cap of $172.0M.
CEORachel E. Haurwitz
Next Earnings
Upcoming earnings announcement for Caribou Biosciences, Inc.
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.32
Revenue Estimate
$2.3M
Earnings History
Past 12 earnings reports for Caribou Biosciences, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$0.28Est: -$0.32 | +12.5% | $3.9MEst: $2.2M | +80.3% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$0.30Est: -$0.36 | +16.7% | $2.2MEst: $2.1M | +2.6% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.35Est: -$0.41 | +14.6% | $2.7MEst: $2.0M | +34.6% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.43Est: -$0.48 | +10.4% | $2.4MEst: $1.4M | +63.4% | 10-Q |
| Mar 10, 2025 | Q4 2024 | -$0.39Est: -$0.42 | +7.1% | $2.1MEst: $1.8M | +12.9% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.38Est: -$0.46 | +17.4% | $2.0MEst: $3.1M | -34.7% | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.42Est: -$0.45 | +6.7% | $3.5MEst: $3.0M | +13.9% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.46Est: -$0.40 | -15.0% | $2.4MEst: $2.9M | -16.2% | 10-Q |
| Mar 11, 2024 | Q4 2023 | -$0.39Est: -$0.37 | -5.4% | $3.6MEst: $4.6M | -22.8% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.12Est: -$0.42 | +71.4% | $23.7MEst: $3.2M | +651.2% | — |
| Aug 8, 2023 | Q2 2023 | -$0.48Est: -$0.49 | +2.0% | $3.8MEst: $3.1M | +22.3% | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.46Est: -$0.49 | +6.1% | $3.5MEst: $3.2M | +11.2% | — |